Fetal Gene Therapy
Fetal Gene Therapy - Related Videos
08:04
Murine Fetal Echocardiography
0 Views •
Cited by 7 •
2013
Fetal and perinatal death is a common feature when studying genetic alterations affecting cardiac development. High-frequency ultrasound imaging has improved 2-D resolution and can provide excellent information on early cardiac development and is an ideal method to detect the impact on cardiac structure and function prior to death.
10:12
A Novel Surgical Approach for Intratracheal Administration of Bioactive Agents in a Fetal Mouse Model
0 Views •
Cited by 8 •
2012
We developed a novel surgical approach for intratracheal administration of bioactive agents into the mouse fetus. The delivery route is more efficient in targeting the fetal mouse lungs than the commonly used intra-amniotic injection. This procedure has to date not been described in a mouse model.
01:22
Gene Therapy
0 Views •
2021
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:22
Gene Therapy
0 Views •
2026
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
14:19
Fetal Echocardiography and Pulsed-wave Doppler Ultrasound in a Rabbit Model of Intrauterine Growth Restriction
0 Views •
Cited by 11 •
2013
We describe examination of fetal cardiac function with contemporary functional fetal echocardiography and fetoplacental Doppler ultrasound using the VisualSonics VEVO 2100 microultrasound in a surgically induced model of intrauterine fetal growth restriction in a rabbit.
FAQs
A vector determines how therapeutic genetic material reaches fetal cells and whether those cells can use the introduced sequence. Fetal gene therapy therefore depends on more than supplying a gene: delivery must reach the relevant developing tissue, support production of a functional protein, and avoid unacceptable fetal harm. Vector-related responses and durability of expression remain central variables in evaluating success.
Immune development is relevant because fetal treatment may take advantage of the developing immune system’s potential for tolerance. If tolerance is achieved, the introduced genetic material may be less likely to provoke problematic vector responses, but that possibility cannot be assumed. Studies must therefore consider immune effects alongside delivery, fetal safety, and the persistence of gene expression.
Timing influences the balance between benefit and risk. Intervention is intended early enough to support a functional protein before disease causes permanent organ damage, while the fetus remains especially dependent on careful safety assessment. Researchers therefore examine whether delivery reaches the affected developing organ, whether expression lasts, and whether the treatment itself creates harmful responses.
Compared with treatment after birth, fetal gene therapy aims to address inherited disease before permanent organ damage has occurred. That timing may broaden the opportunity to influence developing blood, liver, nervous, or skeletal tissues, but it also places the fetus at risk during a sensitive developmental period. The comparison therefore involves both earlier potential benefit and stricter safety concerns.
An in utero research protocol must connect several decisions: the disease-causing mutation, the therapeutic sequence, the vector used to deliver it, and the fetal tissue that requires correction or compensation. Investigators then assess delivery, functional protein production, vector responses, long-term expression, and fetal safety. Ethical oversight is essential because the intervention affects a developing fetus.
Applications are being studied for inherited disorders involving the blood, liver, nervous system, and skeletal tissues. These settings differ in the organs that must receive the therapeutic sequence, so delivery and sustained expression become especially important when judging outcomes. The broader medical goal is to prevent or reduce damage by restoring production of a functional protein before disease becomes irreversible.